Boston Therapeutics, Inc. (BTHE) Prepares For Third Phase Trial Of PAZ320
Small cap
Seeking Alpha Analyst Since 2010
Boston Therapeutics is a pharmaceutical company focused on the development, manufacturing, and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs in diabetes.
PAZ320 is an integral part of the company's initial product pipeline, which is focused on developing and commercializing therapeutic molecules. PAZ320 is a non-systemic, non-toxic, chewable drug which inhibits the enzymes that release glucose from complex carbohydrates in foods during digestion, reducing the amount of available glucose absorbed through the intestine.
In November, Boston Therapeutics enrolled 24 patients with Type 2 diabetes in a Phase IIb clinical study on PAZ320, and positive results from the trial were published by the principal investigator in the July/August issue of the journal "Endocrine Practice". After evaluating the safety and efficacy of PAZ320, it was shown that there was a significant 40% reduction in elevation of post-meal blood glucose in the participating patients, with no serious adverse events.
By the second or third quarter of 2014, the company hopes to begin an important Phase III trial of the chewable tablet it is promoting as a potential adjunct to metformin in patients living with Type 2 diabetes. While the Phase IIb trial was held only in France, the Phase III trial will be multi-national-in the United States, Europe, Hong Kong, and China.
The company believes that PAZ320 is a safe and effective drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels, fulfilling an unmet medical need. The intent is for this compound to provide individuals with a means by which to slow the onset of Type 2 diabetes and/or the onset of diabetes complications such as heart disease, stroke, kidney damage, retinopathy, and Diabetic Foot.
PAZ320 is meant to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down complex carbohydrates into simple sugars, reducing the availability of glucose for absorption into the bloodstream.
For more information about PAZ320 or any of the company's other products, visit the website at bostonti.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.